NASDAQ:KRBP Kiromic BioPharma (KRBP) Stock Price, News & Analysis → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free KRBP Stock Alerts $2.76 +0.09 (+3.37%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$2.75▼$3.0450-Day Range$1.49▼$3.0852-Week Range$0.16▼$5.49Volume725 shsAverage Volume7,188 shsMarket Capitalization$3.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Kiromic BioPharma alerts: Email Address Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company About Kiromic BioPharma Stock (NASDAQ:KRBP)Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.Read More KRBP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRBP Stock News HeadlinesMay 13 at 11:37 AM | investorplace.comKRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024May 13 at 7:14 AM | americanbankingnews.comKiromic BioPharma (NASDAQ:KRBP) Posts Quarterly Earnings ResultsApril 26, 2024 | uk.investing.comDeltacel shows promise in Kiromic BioPharma lung cancer trial, Kiromic seeks FDA fast trackApril 24, 2024 | finance.yahoo.comKiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three PatientsApril 10, 2024 | msn.comKiromic BioPharma files to withdraw registration statementApril 2, 2024 | businesswire.comKiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical TrialMarch 19, 2024 | finance.yahoo.comEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical TrialMarch 19, 2024 | businesswire.comEarly Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical TrialMarch 1, 2024 | businesswire.comKiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 TrialFebruary 28, 2024 | finance.yahoo.comKiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7thFebruary 28, 2024 | businesswire.comKiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7thFebruary 14, 2024 | finance.yahoo.comResults from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsFebruary 14, 2024 | businesswire.comResults from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two MonthsJanuary 29, 2024 | finance.yahoo.comKiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung CancerJanuary 5, 2024 | finance.yahoo.comKiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical TrialDecember 14, 2023 | finance.yahoo.comKiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung CancerNovember 16, 2023 | finance.yahoo.comKiromic BioPharma Announces Uplisting to OTCQB MarketNovember 9, 2023 | finance.yahoo.comKiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer CenterNovember 1, 2023 | morningstar.comKiromic BioPharma Inc Ordinary SharesOctober 23, 2023 | finance.yahoo.comKiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial AgreementSeptember 15, 2023 | uk.investing.comStaidson Beijing Biopharma (300204)September 13, 2023 | finance.yahoo.comKiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14July 24, 2023 | finance.yahoo.comKiromic BioPharma Welcomes Two New Directors to its BoardJune 30, 2023 | marketwatch.comKiromic Biopharma Shares Down 12% After Stock Offering ProspectusJune 10, 2023 | bizjournals.comFounder of multibillion-dollar drug developer Array BioPharma leads Boulder oncology startup in $54M financing roundSee More Headlines Receive KRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KRBP CUSIPN/A CIK1792581 Webwww.kiromic.com Phone832-968-4888FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,950,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-133.33% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.22 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.60) per share Price / Book-0.51Miscellaneous Outstanding Shares1,290,000Free Float1,246,000Market Cap$3.66 million OptionableNot Optionable Beta1.98 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Pietro Bersani CPA (Age 56)J.D., CEO & Director Comp: $891.69kMr. Brian Hungerford (Age 48)Chief Financial Officer Comp: $160.69kDr. Leonardo Mirandola Ph.D. (Age 42)Chief Scientific Officer & Interim COO Comp: $383.32kDr. Scott Dahlbeck M.D. (Age 62)Pharm.D., PharmD, Chief of Staff Comp: $359.08kKey CompetitorsTC BiopharmNASDAQ:TCBPFinch Therapeutics GroupNASDAQ:FNCHAvalon GloboCareNASDAQ:ALBTEloxx PharmaceuticalsNASDAQ:ELOXTRACON PharmaceuticalsNASDAQ:TCONView All Competitors KRBP Stock Analysis - Frequently Asked Questions How have KRBP shares performed in 2024? Kiromic BioPharma's stock was trading at $0.87 at the start of the year. Since then, KRBP stock has increased by 217.2% and is now trading at $2.76. View the best growth stocks for 2024 here. How were Kiromic BioPharma's earnings last quarter? Kiromic BioPharma, Inc. (NASDAQ:KRBP) issued its quarterly earnings data on Friday, May, 10th. The company reported ($1.00) earnings per share (EPS) for the quarter. When did Kiromic BioPharma's stock split? Kiromic BioPharma's stock reverse split on Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Kiromic BioPharma IPO? Kiromic BioPharma (KRBP) raised $16 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 1,200,000 shares at a price of $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Paulson Investment Company was co-manager. How do I buy shares of Kiromic BioPharma? Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRBP) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperPharma Giant Makes Deal with a "Drug Smuggler"Behind the MarketsHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
